{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:13:19Z","timestamp":1790266399339,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Haemophilia\u2010free mind is an aspirational concept defined as a state in which affected individuals are liberated from physical, mental, and treatment burdens of haemophilia. A conceptual framework has been proposed for the haemophilia\u2010free mind that comprises ten dimensions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate changes in achievement towards a haemophilia\u2010free mind in participants with haemophilia A who received valoctocogene roxaparvovec gene therapy in the GENEr8\u20101 trial (NCT03370913), by confirming relevant dimensions, with measures and thresholds for each.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An expert panel comprising four haemophilia clinicians and one patient expert identified dimensions of the haemophilia\u2010free mind relevant to gene therapy. Measures and thresholds were defined for each dimension and used to analyse GENEr8\u20101 data to determine the proportion of participants achieving these thresholds at Baseline and Week 208.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expert panel confirmed 7\/10 dimensions as appropriate for use in gene therapy trials and defined measurement thresholds for each dimension. Among GENEr8\u20101 trial participants, improvements were observed across all seven dimensions. The proportion of participants with zero treated bleeds increased from 33% (Baseline) to 54% (Week 208). Similarly, those reporting no exogenous factor VIII use rose from 0% to 33%. Improvements in perceived burden on family members, physical activity, and travel were 8%, 16%, and 18%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This expert\u2010led analysis demonstrates application of the haemophilia\u2010free mind framework to clinical trial data using existing outcome measures. Mapping GENEr8\u20101 data to this framework demonstrated improvements of up to 33% in domains that contribute towards a haemophilia\u2010free mind in participants after valoctocogene roxaparvovec treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70418","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:12Z","timestamp":1790265372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Gene Therapy on the Haemophilia\u2010Free Mind: Outcomes Before and After Valoctocogene Roxaparvovec in GENEr8\u20101 Trial Participants"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[{"name":"Haemostasis and Thrombosis Unit, Division of Adult Haematology Cliniques Universitaires SaintLuc, Universit\u00e9 catholique De Louvain (UCLouvain)  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Karimi","sequence":"additional","affiliation":[{"name":"BioMarin UK Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Camp","sequence":"additional","affiliation":[{"name":"BioMarin UK Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Pathology University of Michigan  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Santos","sequence":"additional","affiliation":[{"name":"BioMarin UK Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Harris","sequence":"additional","affiliation":[{"name":"BioMarin UK Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Reaney","sequence":"additional","affiliation":[{"name":"IQVIA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hinds","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc.  Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fogarty","sequence":"additional","affiliation":[{"name":"BioMarin Pharmaceutical Inc.  Novato California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Medical Clinic 2 Goethe University Hospital  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milan Italy"},{"name":"Department of Pathophysiology and Transplantation University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"1","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13023-023-02690-w","article-title":"The Impact of Bleeding Event Frequency on Health\u2010Related Quality of Life and Work Productivity Outcomes in a European Cohort of Adults With Haemophilia A: Insights From the Chess II Study","volume":"18","author":"Young L.","year":"2023","journal-title":"Orphanet journal of rare diseases"},{"issue":"5","key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/hae.70078","article-title":"Treatment and Disease Burden in a Cohort of People With Haemophilia Without Inhibitors in the United States","volume":"31","author":"Wheeler A. P.","year":"2025","journal-title":"Haemophilia"},{"issue":"5","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/hae.70051","article-title":"Real\u2010World Unmet Needs of Patients With Haemophilia a and Haemophilia B With or Without Inhibitors: End\u2010of\u2010Study Results From the Explorer6 Non\u2010Interventional Study","volume":"31","author":"Wheeler A. P.","year":"2025","journal-title":"Haemophilia"},{"issue":"9","key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic Arthropathy: Current Knowledge and Future Perspectives","volume":"19","author":"Gualtierotti R.","year":"2021","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"5","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12567","article-title":"Living With a \u201cHemophilia\u2010Free Mind\u201d\u2014The New Ambition of Hemophilia Care?","volume":"5","author":"Krumb E.","year":"2021","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"4","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards Achieving a Haemophilia\u2010Free Mind","volume":"29","author":"Hermans C.","year":"2023","journal-title":"Haemophilia"},{"issue":"6","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd Edition","volume":"26","author":"Srivastava A.","year":"2020","journal-title":"Haemophilia"},{"issue":"8","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1055\/s-0042-1756188","article-title":"The More Recent History of Hemophilia Treatment","volume":"48","author":"Franchini M.","year":"2022","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"3","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/jcm11030801","article-title":"Current Choices and Management of Treatment in Persons With Severe Hemophilia a Without Inhibitors: A Mini\u2010Delphi Consensus","volume":"11","author":"Coppola A.","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"12","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/life14121568","article-title":"Transforming Hemophilia a Care: Insights Into New Therapeutic Options","volume":"14","author":"Iurea I. M.","year":"2024","journal-title":"Life"},{"issue":"1","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the Management of Haemophilia: Emerging Treatments and Their Mechanisms","volume":"28","author":"Okaygoun D.","year":"2021","journal-title":"Journal of Biomedical Science"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","DOI":"10.1177\/23743735231193573","article-title":"Gene Therapy in Hemophilia: A Transformational Patient Experience","volume":"10","author":"Rasul E.","year":"2023","journal-title":"Journal of Patient Experience"},{"issue":"8","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two\u2010Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu J.","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_15_1","unstructured":"United States Food and Drug Administration \u201cValoctocogene Roxaparvovec\u2010Rvox Prescribing Information \u201d Accessed July 05 2026 https:\/\/www.fda.gov\/media\/169937\/download?attachment."},{"key":"e_1_2_13_16_1","unstructured":"European Medicines Agency \u201cInbrija Summary of Product Characteristics \u201d Accessed July 05 2026 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/roctavian\u2010epar\u2010product\u2010information_en.pdf."},{"issue":"8","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, Safety, and Quality of Life 4 Years After Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 Gener8\u20101 Trial","volume":"8","author":"Leavitt A. D.","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"24","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1177\/15353702221147565","article-title":"Gene Therapy for Hemophilia: Looking Beyond Factor Expression","volume":"247","author":"Yamaguti\u2010Hayakawa G. G.","year":"2022","journal-title":"Experimental Biology and Medicine"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1450625","article-title":"The Role of Public Health in Rare Diseases: Hemophilia as an Example","volume":"13","author":"El\u2010Sayed A. A.","year":"2025","journal-title":"Front Public Health"},{"issue":"2","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jth.15570","article-title":"Invisible Bleeds: Lived Experiences and Barriers to Care for Men With Hemophilia","volume":"20","author":"Arya S.","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12488","article-title":"Patient\u2010Relevant Health Outcomes for Hemophilia Care: Development of an International Standard Outcomes Set","volume":"5","author":"Balen E. C.","year":"2021","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"11","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo M. C.","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three\u2010Year Outcomes of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"22","author":"Madan B.","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/hae.14926","article-title":"The Psychosocial Impact of Haemophilia From Patients' and Caregivers' Point of View: The Results of an Italian Survey","volume":"30","author":"Fornari A.","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.36469\/jheor.2024.123374","article-title":"Patient Experience of Living With Hemophilia A: A Conceptual Model of Humanistic and Symptomatic Experience in Adolescents, Adults, and Children","volume":"11","author":"Hakimi Z.","year":"2024","journal-title":"Journal of Health Economics and Outcomes Research"},{"issue":"12","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1016\/j.jtha.2023.08.032","article-title":"Health\u2010Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial Gener8\u20101","volume":"21","author":"O'Mahony B.","year":"2023","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jvh.13882","article-title":"The Benefits of Gene Therapy in People With Haemophilia","volume":"31","author":"Thornburg C. D.","year":"2024","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting Higher Factor VIII Levels for Prophylaxis in Haemophilia A: A Narrative Review","volume":"29","author":"Malec L.","year":"2023","journal-title":"Haemophilia"},{"issue":"7","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jtha.2025.02.042","article-title":"Corticosteroid Use to Mitigate Transaminitis\u2010Associated Decline in FVIII Levels Following Valoctocogene Roxaparvovec Gene Therapy: Clinical Practice Guidance","volume":"23","author":"Konkle B. A.","year":"2025","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13023-024-03181-2","article-title":"A 360\u2010Degree Perspective on Adeno\u2010Associated Virus (AAV)\u2010Based Gene Therapy for Haemophilia: Insights From the Physician, the Nurse and the Patient","volume":"19","author":"Miesbach W.","year":"2024","journal-title":"Orphanet Journal of Rare Diseases"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70418","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:17Z","timestamp":1790265377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":29,"alternative-id":["10.1111\/hae.70418"],"URL":"https:\/\/doi.org\/10.1111\/hae.70418","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"2026-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hae.70418"}}